Anixa Biosciences Inc (NASDAQ:ANIX) Given Consensus Recommendation of “Hold” by Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has been assigned a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.50.

A number of analysts have recently commented on the company. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Finally, Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 19th.

Anixa Biosciences Trading Up 1.1%

Anixa Biosciences stock opened at $3.66 on Wednesday. The stock has a fifty day moving average price of $3.26 and a 200 day moving average price of $2.96. Anixa Biosciences has a 52 week low of $2.32 and a 52 week high of $5.46. The firm has a market capitalization of $124.51 million, a P/E ratio of -11.81 and a beta of 0.55.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, equities analysts predict that Anixa Biosciences will post -0.31 EPS for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, CEO Amit Kumar acquired 21,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was bought at an average cost of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the purchase, the chief executive officer directly owned 630,812 shares in the company, valued at $1,577,030. This represents a 3.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased 50,024 shares of company stock worth $148,971 over the last 90 days. Insiders own 26.40% of the company’s stock.

Institutional Trading of Anixa Biosciences

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Anixa Biosciences by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after buying an additional 7,271 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Anixa Biosciences by 1.7% in the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $559,000. Finally, State Street Corp raised its holdings in shares of Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock valued at $496,000 after buying an additional 38,540 shares during the period. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.